Lazard Asset Management LLC lessened its position in shares of Sotera Health (NYSE:SHC – Get Rating) by 99.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 8,691 shares of the company’s stock after selling 4,660,379 shares during the quarter. Lazard Asset Management LLC’s holdings in Sotera Health were worth $59,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new stake in Sotera Health in the 3rd quarter valued at $75,000. Cipher Capital LP bought a new position in Sotera Health in the 3rd quarter valued at $77,000. MetLife Investment Management LLC bought a new position in Sotera Health in the 1st quarter valued at $139,000. Federated Hermes Inc. bought a new position in Sotera Health in the 1st quarter valued at $157,000. Finally, Barclays PLC raised its position in Sotera Health by 50.5% in the 3rd quarter. Barclays PLC now owns 23,171 shares of the company’s stock valued at $158,000 after purchasing an additional 7,773 shares during the last quarter. Institutional investors and hedge funds own 87.21% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. Barclays upgraded Sotera Health from an “underweight” rating to an “overweight” rating and lifted their price objective for the company from $6.00 to $22.00 in a research report on Tuesday, January 10th. JPMorgan Chase & Co. raised Sotera Health from an “underweight” rating to a “neutral” rating and upped their price target for the company from $6.00 to $18.00 in a research note on Monday, January 23rd. Royal Bank of Canada lifted their price objective on Sotera Health from $8.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. Wolfe Research upgraded shares of Sotera Health from a “peer perform” rating to an “outperform” rating and set a $25.00 target price on the stock in a research report on Tuesday, January 10th. Finally, The Goldman Sachs Group reduced their target price on shares of Sotera Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 23rd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and an average target price of $16.83.
Sotera Health Stock Down 1.3 %
Sotera Health Company Profile
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.
- Get a free copy of the StockNews.com research report on Sotera Health (SHC)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding SHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sotera Health (NYSE:SHC – Get Rating).
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.